Media news (journalist wan woo)East sunshine section(600673) in the evening announcement of 30 may, the company was notified on that day that the m & as review board of the cvm would recently review the purchase of assets and related transactions by the company, and that the stock of the company would be closed tomorrow (31 may)。
This is the first time an audit has been suspended for three months, east sunshineAcquisitionEast sunshineRecent significant developments in controlling equity matters. According to the information, the company had previously stopped on 1 march to review the purchase of east sunshine medicines and had subsequently suspended its verification of major matters, pending clarification as to whether to resume the audit as appropriate。
According to the reorganization report previously disclosed by the company, the listed company intends to purchase its share of 226. 2 million shares (50. 04 per cent of its total equity) of east sunshine medicine at a total cost of rmb 3,221 million from the ii changdong sun medicines industry. When the deal is completed, the east sunshine medicine will become a holding subsidiary of the listed company。
According to the data, east sunshine was established in 2001 as a pharmaceutical company with antiviral drugs at its core, covering the development, production and marketing of drugs for the treatment of diseases such as antivirus, endocrine and cardiovascular diseases, and successfully listed on the main board of hong kong joint exchange in 2015. The yi changdong sun medicines industry committed itself in the profit forecast compensation agreement to a net profit of not less than 577 million yuan in 2018, 653 million yuan in 2019 and 689 million yuan in 2020。
According to the annual report for 2017, disclosed on 30 april, during the reporting period the company achieved operating income of $1. 602 billion, an increase of 70. 11 per cent over the same period, and net profits of $647 million, an increase of 70. 02 per cent over the same period, showing high growth. It is worth noting that the share of corporate core products in total turnover for the year is 87. 49 per cent. But viv is the dominant product in the domestic market for phosphate othate products, and there were multiple cases of “one cure is not available” during the flu outbreak in early 2018, which is expected to occur throughout the yearPerformanceProvide good support。
According to the 2017 annual report of the east sunshine section, listed companies also handed over a very bright performance. The company achieved operating income of $7. 412 billion in 2017, an increase of 45. 27 per cent over the same period, and net profits of $523 million, an increase of 377. 76 per cent over the same period。
It was pointed out that the company, the national electronic aluminum lead firm, had benefited from the rise in the price of electrodes and that the main business would continue to improve, while the acquisition of east sunshine medicine would add new growth points to the company's performance. The two-wheel drive of the electronic aluminum and pharmaceutical industries will be achieved in the future and performance will maintain rapid growth。
